Acarbose — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	12.5-25 mg per dog (or 1-3 mg/kg) initially, titrate up to 25-50 mg per dog q12h	q12h (every 12 hours) with meals	Duration: Long-term, as needed for glycemic control Notes: Start with a low dose and increase gradually over 1-2 weeks to minimize gastrointestinal side effects. Administer with the first bite of a meal to ensure adequate mixing with food.
Cat	PO	12.5-25 mg per cat (or 1-2 mg/kg) q12h	q12h (every 12 hours) with meals	Duration: Long-term, as needed for glycemic control Notes: Titrate slowly; monitor for diarrhea and weight loss. May be used in combination with insulin.
Horse	PO	Not established; experimental doses of 1-3 mg/kg q12h have been used in research settings	q12h	Duration: Not established Notes: Not routinely used; limited evidence for efficacy in equine metabolic syndrome.

Clinical Indications & Species Uses

General Indications

Adjunct treatment of diabetes mellitus in small animals (dogs and cats) to reduce postprandial hyperglycemia

Dog (Canine)

Adjunct therapy for diabetes mellitus (type 1 or type 2) to improve postprandial glycemic control
Management of insulin resistance in diabetic dogs

Cat (Feline)

Adjunct therapy for diabetes mellitus (type 2) to improve postprandial glycemic control
Management of diabetic cats with poor response to insulin alone

Pharmacology & Mechanism of Action

Drug Class: Alpha-glucosidase inhibitor | Pharmacological Group: Antidiabetic agent (oral hypoglycemic)

Mechanism of Action: Acarbose is a complex oligosaccharide that competitively and reversibly inhibits alpha-glucosidase enzymes in the brush border of the small intestine. These enzymes (including sucrase, maltase, and glucoamylase) are responsible for the breakdown of complex carbohydrates and disaccharides into absorbable monosaccharides. By inhibiting these enzymes, acarbose delays the digestion and absorption of carbohydrates, thereby reducing postprandial hyperglycemia. It does not stimulate insulin secretion and has no direct effect on glucose metabolism.

Pharmacodynamics: Acarbose reduces the rate of glucose absorption from the gastrointestinal tract, leading to a lower postprandial rise in blood glucose. It also reduces the secretion of glucose-dependent insulinotropic peptide (GIP) and may improve overall glycemic control in diabetic patients. Chronic use may lead to a modest reduction in fasting blood glucose and HbA1c levels. The drug acts locally in the gut and is minimally absorbed systemically.

⚡ Pharmacokinetics Summary

Absorption: Acarbose is minimally absorbed from the gastrointestinal tract; less than 2% of the administered dose is absorbed as the parent compound. The absorbed fraction is mostly metabolized by intestinal bacteria and digestive enzymes.

Distribution: The absorbed fraction is distributed mainly in the extracellular fluid. The volume of distribution is not well characterized in veterinary species. It does not cross the blood-brain barrier significantly.

Metabolism: Acarbose is metabolized exclusively within the gastrointestinal tract by intestinal bacteria and digestive enzymes, producing various metabolites, including glucose and other oligosaccharides. The liver is not significantly involved in its metabolism.

Excretion: The majority of the drug (about 50-60%) is excreted in the feces as unabsorbed drug and metabolites. A small fraction (about 1-2%) is excreted in the urine as metabolites. In animals with renal impairment, systemic exposure may increase slightly.

Half-Life: The plasma half-life of acarbose is approximately 2 hours in humans; in veterinary species, it is likely similar but not well documented. However, because the drug acts locally, the half-life is not clinically relevant.

Bioavailability: Oral bioavailability is very low (less than 2%) due to poor absorption and local degradation.

Protein Binding: Protein binding is low (less than 1%) in humans; in veterinary species, it is expected to be low.

Available Formulations & Strengths

Oral Tablet 25 mg, 50 mg, 100 mg (PO)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to acarbose or any component of the formulation
Diabetic ketoacidosis
Inflammatory bowel disease, colonic ulceration, or partial intestinal obstruction
Chronic intestinal diseases associated with disorders of digestion or absorption
Renal impairment (creatinine clearance < 25 mL/min in humans; use with caution in animals with significant renal disease)
Pregnancy and lactation (safety not established; use only if clearly needed)

Warnings & Clinical Precautions:

Use with caution in animals with hepatic disease (limited data)
Monitor blood glucose regularly; adjust insulin doses as needed
May cause gastrointestinal side effects (flatulence, diarrhea, abdominal discomfort) especially at the start of therapy; titrate dose slowly
Do not use as monotherapy in animals with severe insulin deficiency (type 1 diabetes); it is an adjunct to insulin
In case of hypoglycemia, use oral glucose (dextrose) rather than sucrose (table sugar) because sucrose digestion is inhibited
Not for use in food-producing animals due to lack of withdrawal time data
Store in a cool, dry place; keep out of reach of children and animals

Adverse Effects & Reactions

Common:

Flatulence
Diarrhea
Abdominal discomfort
Soft stools
Reduced appetite

Serious / Severe:

Severe diarrhea leading to dehydration and electrolyte imbalance
Hepatotoxicity (rare, reported in humans; monitor liver enzymes in long-term therapy)
Hypoglycemia when used in combination with insulin or sulfonylureas

Rare:

Ileus
Pneumatosis cystoides intestinalis (in humans)
Allergic reactions (rash, urticaria)

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Insulin	Additive hypoglycemic effect; may require insulin dose reduction	High
Oral sulfonylureas (e.g., glipizide)	Additive hypoglycemic effect; monitor blood glucose	High
Digoxin	Acarbose may reduce the absorption of digoxin; monitor digoxin levels	Moderate
Warfarin	Potential for increased anticoagulant effect; monitor coagulation parameters	Moderate
Intestinal adsorbents (e.g., activated charcoal)	May reduce the efficacy of acarbose; separate administration times	Mild
Digestive enzymes (e.g., amylase, pancreatic enzymes)	May reduce the efficacy of acarbose; separate administration times	Mild

Overdose & Toxicity Management

Signs of Toxicity:

Gastrointestinal distress (flatulence, diarrhea, abdominal pain)
Hypoglycemia (if combined with insulin or other hypoglycemic agents)
Lethargy, weakness, tremors (due to hypoglycemia)

Emergency Treatment Protocol: There is no specific antidote for acarbose overdose. Treatment is symptomatic and supportive. For acute overdose, induce vomiting (if recent and animal is stable) and administer activated charcoal. Monitor blood glucose and treat hypoglycemia with oral or parenteral dextrose (note: sucrose will not be effective). Provide fluid and electrolyte replacement for diarrhea. In severe cases, hospitalization may be required.

Food Animal Withdrawal Times

Not approved for use in food-producing animals. Do not use in animals intended for food production.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature (20-25°C, excursions permitted to 15-30°C)

Handling & Special Conditions: Keep in a tight, light-resistant container. Protect from moisture.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; approved for human use (Precose).

Extra-Label (Off-Label) Use: In the US, acarbose is not FDA-approved for veterinary use; its use in animals is extra-label. Under AMDUCA, extra-label use is permitted in non-food animals (e.g., dogs, cats) by or on the order of a licensed veterinarian. Use in food animals is prohibited due to lack of withdrawal times.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Acarbose is used as an adjunctive therapy in diabetic dogs and cats, particularly when postprandial hyperglycemia is difficult to control with insulin alone. It is not a substitute for insulin in insulin-dependent diabetics. The drug works by delaying carbohydrate absorption, so it must be administered with meals. Gastrointestinal side effects are common but can be minimized by starting with a low dose and gradually increasing. Monitor blood glucose curves and adjust insulin doses accordingly. In cats, acarbose may be less effective due to their carnivorous diet (low carbohydrate), but it can still be beneficial in some cases. Always ensure the animal has access to fresh water. Do not use in food animals. Client education is important: if hypoglycemia occurs, administer glucose (dextrose) rather than table sugar, as acarbose inhibits sucrose digestion.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)